Stockscreener 앱 받기
9.43
0.49%
0.02
전일 마감가:
$9.41
열려 있는:
$9.61
하루 거래량:
41,202
Relative Volume:
0.04
시가총액:
$212.21M
수익:
$146.07M
순이익/손실:
$-196.04M
주가수익비율:
-0.5674
EPS:
-16.621
순현금흐름:
$-75.37M
1주 성능:
+12.58%
1개월 성능:
+49.63%
6개월 성능:
+81.16%
1년 성능:
+50.82%
1일 변동 폭
$9.30
$9.61
1주일 범위
$8.1728
$9.61
52주 변동 폭
$3.6503
$10.99
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
명칭
Karyopharm Therapeutics Inc
전화
617-658-0600
주소
85 WELLS AVENUE, NEWTON, MA
Compare KPTI vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
9.41 | 212.21M | 146.07M | -196.04M | -75.37M | -16.62 |
VRTX
Vertex Pharmaceuticals Inc
|
428.24 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
720.25 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
812.87 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.81 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.29 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-10 | 개시 | Rodman & Renshaw | Buy |
| 2026-02-05 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-10-13 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-07-16 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-07-11 | 재개 | H.C. Wainwright | Buy |
| 2023-01-19 | 개시 | Piper Sandler | Overweight |
| 2022-11-04 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-11-19 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-08-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-08-06 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | 개시 | Morgan Stanley | Overweight |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-17 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-07-23 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-07-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-05 | 재확인 | Robert W. Baird | Outperform |
| 2019-03-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-02-28 | 재확인 | BofA/Merrill | Underperform |
| 2019-02-27 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | 개시 | B. Riley FBR | Buy |
| 2018-11-09 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2018-05-24 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-04-02 | 재개 | Leerink Partners | Outperform |
| 2017-11-15 | 재개 | H.C. Wainwright | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2016-09-08 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-30 | 업그레이드 | Jefferies | Hold → Buy |
| 2016-08-18 | 개시 | H.C. Wainwright | Buy |
| 2016-06-28 | 개시 | Robert W. Baird | Outperform |
모두보기
Karyopharm Therapeutics Inc 주식(KPTI)의 최신 뉴스
Karyopharm (NASDAQ: KPTI) registers resale of 8.843M shares from private placement - Stock Titan
Karyopharm Therapeutics: Selling stockholder may resell up to 8,843,036 shares of Karyopharm common stockSEC filing - marketscreener.com
Karyopharm Therapeutics: Selling Stockholder May Resell Up To 8,843,036 Shares Of Karyopharm Common StockSEC Filing - TradingView
Karyopharm Therapeutics may offer up to $400 million in securitiesSEC filing - marketscreener.com
Karyopharm Therapeutics (NASDAQ: KPTI) files $400M shelf, $100M ATM with Jefferies - Stock Titan
Karyopharm (KPTI) Q1 2025 Earnings Transcript - AOL.com
Karyopharm to seek label expansion for Xpovio in myelofibrosis after late-stage trial win - MSN
KPTI stock down on mixed phase III myelofibrosis combo study data - MSN
KPTI stock slumps pre-market even as Karyopharm’s myelofibrosis treatment meets primary endpoint — retail doubtful about FDA approval - MSN
Karyopharm Therapeutics (KPTI) price target increased by 13.33% to 13.87 - MSN
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Piper Sandler Reiterates Overweight Rating for Karyopharm Therapeutics (NASDAQ:KPTI) - MarketBeat
KPTI Upgraded by Piper Sandler -- Price Target Raised to $16.00 - GuruFocus
Piper Sandler Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Raises Target Price to $16 - Moomoo
Karyopharm Therapeutics jumps 18%, raises $30M privately - MSN
Karyopharm Therapeutics (KPTI) price target decreased by 22.08% to 12.24 - MSN
Is Karyopharm Therapeutics (KPTI) stock considered a safe play | Q4 2025: Below ExpectationsPricing Power - Cổng thông tin điện tử tỉnh Lào Cai
Karyopharm (KPTI) CMO logs pre-planned tax-related sale of 449 shares - Stock Titan
Karyopharm’s myelofibrosis trial selected for ASCO presentation By Investing.com - Investing.com Australia
Karyopharm’s myelofibrosis trial selected for ASCO presentation - Investing.com
Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting - Karyopharm
Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Passes Above 50 Day Moving AverageWhat's Next? - MarketBeat
Is Karyopharm Therapeutics (KPTI) stock a smart investment today (Bullish Sentiment) 2026-04-20Risk Reward Ratio - Cổng thông tin điện tử tỉnh Lào Cai
RBC Flags Seasonal Pressures Impacting Karyopharm Therapeutics Inc. (KPTI) Short-Term Performance - Insider Monkey
KPTI SEC FilingsKaryopharm Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Karyopharm Therapeutics : Corporate Presentation - marketscreener.com
Karyopharm Therapeutics Inc (KPTI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.78%
3.01%
자본화:
|
볼륨(24시간):